CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
SLIDE-HCC: Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable hepatocellular carcinoma
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Docetaxel and Hormone Treatment compared to Hormone Treatment alone in people with Metastatic Castration Sensitive Prostate Cancer and Less than Optimal PSA Response (TRIPLE-SWITCH)
The Canadian Cancer Research Alliance (CCRA) announced the recipients of its biennial awards, recognizing significant contributions to cancer research in Canada.
Results from a phase III international study (IND.227) were recently published in The Lancet and evaluated the use of the immunotherapy drug pembrolizumab combined with platinum-pemetrexed chemotherapy. Researchers conclude that as a first-line treatment for patients with unresectable advanced or metastatic pleural mesothelioma, pembrolizumab plus platinum-pemetrexed chemotherapy represents a new treatment option for patients.
The Pharmacy Network is actively seeking volunteers for Disease Site Representative positions in both Gastrointestinal and Lung.
It is with great sadness that we acknowledge the passing of CCTG Patient Representative Sylvie Desmarais, after her four year battle with metastatic breast cancer. Her main mission was as a patient partner, supporting the advancement of research and services for women with breast cancer.
Congrats to the 2023-2024 Practicum participant who successfully completed their in person visit to CCTG Central Offices in Kingston, Ontario October 5th 6th, 2023. During their visit the group participated in the following sessions:
